Jobs

Parallel Bio develops tools that help in the discovery and development of immunotherapies to eliminate current barriers and create the fastest path to a drug that works. Parallel Bio's platform combines best-in-class human immune organoids with computational methods to generate unprecedented insights into human health and disease.

We're Twelve, the carbon transformation company. We turn CO2 into chemicals, materials, and fuels through the science of electrochemistry and technology that works like industrial photosynthesis.

Transfyr.bio is developing AI-powered tools to help capture, translate, and transfer the unspoken "know-how" that is crucial for successful biotech innovation.

At Reach Industries, we are an early stage start-up with a mission to augment scientists and make labs more efficient, so they can better and faster tackle world challenges. Our intelligent platform, Lumi™, leverages computer vision, voice, and machine learning to capture and analyze operational data. It works as a true assistant across all stages of life sciences development, from research to production environments. Lumi™ starts by automating the capture of data associated with experiments, observations, and material usage, and can do so much more. Lumi™ saves valuable time, so that scientists can focus on the science and more important matters and increase reproducibility.

Based in Boston, MA, STRM.BIO (“Storm Bio”) is a pre-clinical, VC-backed biotechnology company that aims to fulfill the promise of gene therapy by leveraging Extracellular Vesicles (EVs) to deliver treatment directly to the patient (in vivo). Unlike viruses, EVs are natural carriers of nucleic acids and proteins with innate targeting capabilities, amenability to large scale/commercial manufacture, and low immunogenicity – which make them excellent cell messengers for gene therapies. Our proprietary EV platform is establishing a whole new class of therapeutics, yielding new therapies and making existing ones more effective. At STRM.BIO, we believe that our work has the potential to democratize gene therapy and bring hope for patients fighting rare diseases worldwide. We are currently recruiting team members who can help us make our vision a life-saving reality.

EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.

Checkerspot is a biotechnology company designing materials and ingredients at a molecular level to enable more sustainable and high-performing products. By optimizing microalgae, Checkerspot’s vertically integrated Wing™ platform biomanufactures unique oils that replace commodity oils and petroleum-based inputs and improve performance properties in targeted hardgoods, textiles, and personal care products.

Zymochem is breakthrough science for a fossil-free future. We accelerate the transition to a real-zero economy by developing bio-based materials for everyday products. Are you interested in learning more about how our high-performance biomaterials are replacing petrochemical ingredients? We are seeking candidates who are motivated by science and innovation and have a passion to push the boundaries of materials performance. We are collaborative, multidisciplinary, and relentlessly committed to creating a chemicals and materials industry in tune with the 21st century. If this sounds exciting, we want to hear from you! Please visit: www.zymochem.com/careers Zymochem. Creating the fossil-free future.

We build sensory reasoning models that go beyond the human capacity. General Sense captures real-world chemical telemetry through neural decoding, unlocking the sensory data needed for complete world models.

Autoimmune disease is best treated by targeting its cellular origin Patients with autoimmune disease deserve therapies designed specifically for them Genomics and AI can massively accelerate our path to building exceptional medicines Small teams can win through focus, nimbleness and pace of execution Together, we can transform how we care for patients with autoimmune disease.

Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics or SMTHs, designed to address complex diseases by targeting rare combinations of proteins that work together. Using its proprietary Locksmith platform, the company is advancing programs across multiple therapeutic areas to create new options for patients with common, hard-to-treat conditions.

Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.